Skip to main content

Home/ MaRS/ Group items tagged Therapeutics collaboration

Rss Feed Group items tagged

Assunta Krehl

* Printer friendly version * Email story to a friend * Send your comments to th... - 1 views

  •  
    MaRS Innovation (MI) and the Centre for Drug Research and Development (CDRD) are pleased to announce that they have entered into an agreement to collaborate on projects of mutual interest with a goal to advance and commercialize early-stage health-related discoveries. Dec 15, 2009
Assunta Krehl

MaRS Innovation and CDRD Announce Strategic Collaboration - Canada Newswire - 0 views

  •  
    "MaRS Innovation (MI) and the Centre for Drug Research and Development (CDRD) are pleased to announce that they have entered into an agreement to collaborate on projects of mutual interest with a goal to advance and commercialize early-stage health-related discoveries." Nov 30, 2009
Assunta Krehl

Scratching The Biotech Surface - Backbone Magazine - 0 views

  • We don’t know for sure,” said Dr. John Evans, chair of the board of directors at MARS (Medical and Related Sciences) Discovery District in Toronto, and vicechair of Mississauga, Ont.-based NPSAllelix Biopharmaceuticals, one of the pioneers of biotech in Canada.

    “But we believe that if you could ‘type’ the patient processes of how he/she handles a drug, you could peel off those people who would be particularly sensitive to a drug.

    Then you could find a sub-population where the drug is safe and highly effective.”

    Evans used the arthritis drug Vioxx as an example. It helped millions of people battle painful inflammation, but was pulled from the market recently because of potential cardiac side effects in some people.

    “If the drug company could have predicted which patients would have complications from Vioxx treatment — through some genetic profiling — then a very powerful and effective drug could have been preserved,” Evans said.

    His company, NPS-Allelix Bio-pharmaceuticals, has been developing a product since 1989 that will be launched later this year. The drug secretes a parathyroid hormone for treating osteoporosis.

  • It builds up bone matrix and helps build bone, rather than just delay bone loss as other drugs do.
  •  
    The field of biotechnology is a collaboration between research disciplines who have a quantitative view of the world. A review of how human genome affects drug development is reviewed.
  •  
    The field of biotechnology is a collaboration between research disciplines who have a quantitative view of the world. A review of how human genome affects drug development is reviewed. Sept 11, 2005
Assunta Krehl

MaRS Discovery District - News - News Releases - 2009 - MaRS Innovation selects diabeti... - 0 views

  • MaRS Innovation and The University of Toronto (U of T) are pleased to announce that they have entered into an agreement to collaboratively commercialize a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers. 
  • This wound healing technology is extremely exciting, making it an early commercialization opportunity that MaRS Innovation has identified as being a potential win for some 45 million diabetics globally,” said Dr. Rafi Hofstein, President and CEO of MaRS Innovation. 
  • disruptive technology that facilitates continued therapeutic release of NO over a two week period has been developed by Dr. Ping Lee, Professor at the Leslie Dan Faculty of Pharmacy and GlaxoSmithKline Chair in Pharmaceutics and Drug Delivery at U of T.
  • ...4 more annotations...
  • This is one of many new commercilization ventures that will be initiated by MaRS Innovation, our partner in commercialization of research with 13 other academic institutions across the Greater Toronto Area,” said Paul Young, U of T’s Vice-President, Research. “We at U of T are delighted that this innovation from Dr. Lee will be taken to the marketplace to the benefit of society and the economy of Ontario and Canada.” 
  • With the launch of this second commercial opportunity, MaRS Innovation will continue to aggregate the exceptional science of its institutional members by being a one-stop commercialization centre for industry, entrepreneurs and investors. MaRS Innovation is expediting the transformation of the Toronto-based research into a powerful commercialization engine. 
  • “MaRS Innovation is deeply committed to facilitating strategic research collaborations with industry partners, strengthening the innovation capacity of Canadian industry through adoption of new technologies, and launching a new generation of robust, high-growth Canadian companies that will become global market leaders,” added Dr. Hofstein. “We look forward to working closely with all of our institutional members and to continue to jointly announce
    exciting commercial opportunities.”
  • MaRS Innovation is dedicated to bringing brilliant discoveries to market by converting the outstanding science of its member institutions into outstanding economic results for Canada and the world.
  •  
    MaRS Innovation and The University of Toronto (U of T) announce that they have entered into an agreement to collaboratively commercialize a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers.
1 - 4 of 4
Showing 20 items per page